InsidersTradesSigma
Track the EDGEWISE THERAPEUTICS INC stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €4.7bn. The latest transaction was disclosed on 13 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: JOANNE DONOVAN. The full history is accessible without an account.
Analysts rate EDGEWISE THERAPEUTICS INC Buy (bullish), based on 13 analysts. Average price target: US$51.15.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
EDGEWISE THERAPEUTICS INC is a biopharmaceutical company focused on developing treatments for rare genetic diseases. It employs an innovative approach to design targeted therapies.